Search Results for: Mrna

Immunogenicity and safety study of a single dose of SpikoGen® vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.

Immunogenicity and safety study of a single dose of SpikoGen® vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.

Coronavirus Literature
Publication date: Feb 05, 2025 Concepts Keywords 3rd Adjuvant Driving Advax-CpG Nct05542862 COVID-19 Nuclear Delta inulin Vaccine Pandemic SARS-CoV-2 Vaccine Semantics Type Source Name disease IDO protein disease MESH breakthrough ... Read more
Immunogenicity and safety study of a single dose of SpikoGen® vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.

Immunogenicity and safety study of a single dose of SpikoGen® vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.

Coronavirus Literature
Publication date: Feb 05, 2025 Concepts Keywords 3rd Adjuvant Driving Advax-CpG Nct05542862 COVID-19 Nuclear Delta inulin Vaccine Pandemic SARS-CoV-2 Vaccine Semantics Type Source Name disease IDO protein disease MESH breakthrough ... Read more
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses.

Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses.

Coronavirus Literature
Publication date: Feb 04, 2025 Individuals with primary and secondary immunodeficiencies, being more susceptible to infections, are a priority for vaccination. Here, we determined and compared in a longitudinal study ... Read more